AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid

AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one-time gene silencing in the central nervous system AviadoBio will present key data on AVB-406 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting